Financial Performance - The company incurred a net loss of $30.0 million for the fiscal year ended December 31, 2023, compared to a loss of $32.1 million in 2022, with an accumulated deficit of approximately $396.8 million as of the end of 2023[158]. - The company expects to continue incurring significant losses as it advances research and development for roluperidone and other product candidates, with future losses potentially increasing[159]. - As of December 31, 2023, the company had cash, cash equivalents, and restricted cash totaling $41.0 million, which is expected to meet cash commitments for at least the next 12 months[161]. - The company will require additional capital to finance operations and product development, with potential challenges in raising funds due to global economic conditions[162]. - The company has approximately $126.2 million in federal net operating losses (NOLs) as of December 31, 2023, with some NOLs beginning to expire in 2036 if not utilized[168]. - The company has no products approved for commercial sale and has not generated any revenue from product sales to date, indicating a high level of financial risk[158]. Regulatory Approval and Clinical Trials - The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of February 26, 2024, for the review of the NDA for roluperidone, following a previous refusal to file[157]. - The FDA filed the NDA for roluperidone on April 27, 2023, with a PDUFA goal date of February 26, 2024[174]. - The FDA identified potential review issues including the efficacy and safety of roluperidone in patients requiring antipsychotic treatment[174]. - The Phase 3 trial of roluperidone failed to meet its primary endpoint, despite the Phase 2b trial achieving statistical significance[178]. - Regulatory authorities may require additional studies or data, which could increase costs and delay the approval process[174]. - The company has no experience in advancing product candidates beyond Phase 3, which complicates the assessment of its commercialization capabilities[186]. - Enrollment challenges in clinical trials may arise due to the mental health conditions of subjects, impacting timely completion[187]. - The results of clinical trials conducted outside the U.S. may not be accepted by the FDA, potentially necessitating additional trials[179]. - The company may face significant setbacks in clinical trials due to safety or efficacy concerns, which are common in the pharmaceutical industry[178]. - Regulatory approval processes may be impacted by government funding issues or global health concerns, affecting review times[184]. - The company has previously discontinued development of MIN-117 for MDD after failing to achieve its primary endpoint in a Phase 2b trial[188]. - The company is prioritizing the development of its most advanced product candidate, roluperidone, while suspending further development of MIN-301[191]. - Regulatory approval for product candidates may be delayed or granted for narrower indications than expected, impacting commercialization timelines[192]. - Approved products will be subject to ongoing regulatory obligations, which may result in significant expenses and limit commercialization capabilities[194]. - Changes in drug indications, labeling, or safety issues may require additional regulatory submissions, potentially delaying market entry[195]. - The regulatory pathway for MIN-301 has not yet been determined, and the company plans to discuss the appropriate regulatory requirements with the FDA[208]. - The European Commission's proposal to revise pharmaceutical legislation may decrease data and market exclusivity for product candidates in the EU[206]. - Compliance with the new EU Clinical Trials Regulation may impact development plans and timelines[205]. Market and Competitive Landscape - The biopharmaceutical industry is highly competitive, with major pharmaceutical companies and biotechnology firms posing significant challenges due to their greater resources[212]. - Competitors may achieve regulatory approval faster or develop more effective products, which could hinder the company's market position[213]. - The company currently has a limited marketing and sales organization, which may impede its ability to effectively commercialize approved products[218]. - If the company commercializes its product candidates, it may face unfavorable pricing regulations and reimbursement practices that could adversely affect revenue[225]. - Coverage and adequate reimbursement from third-party payors are critical for product acceptance, and any limitations could materially harm the company's business[229]. - The company anticipates that pricing negotiations in international markets may delay product launches and impact revenue generation[226]. - The introduction of cost-containment measures in the EU could lead to price reductions and affect the company's ability to recoup investments in product development[228]. - The U.S. federal government may impose mandatory additional rebates and discounts on drug manufacturers if commercial prices increase faster than the Consumer Price Index-Urban, potentially impacting the ability to raise commercial prices[232]. - Coverage and reimbursement for drug products in the U.S. can vary significantly among third-party payors, leading to a time-consuming and costly coverage determination process[233]. - There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, which could adversely affect the commercialization of product candidates[235]. - The Inflation Reduction Act of 2022 allows HHS to negotiate prices for certain drugs under Medicare, which could significantly impact the pharmaceutical industry[237]. - The EU's Regulation No 2021/2282 on Health Technology Assessment, effective January 2025, aims to enhance cooperation among EU Member States in assessing health technologies, potentially affecting pricing and reimbursement[244]. - The legislative landscape in the U.S. and EU continues to evolve, with potential future measures that may impose more rigorous coverage criteria and lower reimbursement rates[241]. - The UK’s withdrawal from the EU may lead to additional regulatory challenges and costs for drug manufacturers, particularly regarding batch testing and release requirements[249]. - Currency fluctuations, especially with the Euro, could significantly impact the costs of conducting clinical trials in Europe[246]. - The company may face increased operational risks due to geopolitical instability and public health issues, which could adversely affect business prospects[247]. - The company may need to compile additional data for cost-effectiveness assessments in some EU Member States to obtain reimbursement for its products[243]. Legal and Compliance Risks - The company faces significant risks related to product liability claims, which could result in substantial liabilities and limit the commercialization of its product candidates[263]. - The company does not currently carry product liability insurance, which may hinder its ability to commercialize products if claims arise[264]. - The company actively evaluates strategic transactions and may pursue acquisitions or joint ventures, but lacks substantial experience in integrating acquired businesses[260]. - The potential divergence of UK legislation from EU regulations post-Brexit could materially impact the company's regulatory regime and development plans[252]. - The company may incur significant additional expenses due to delays in obtaining regulatory approvals, which could adversely affect its ability to generate revenue[253]. - The company is highly dependent on key personnel, and the loss of such individuals could harm its business and financial condition[254]. - The company must manage its growth effectively to maintain relationships with strategic partners and ensure successful commercialization of its product candidates[258]. - The company faces challenges in maintaining effective internal controls over financial reporting, which could affect investor confidence and stock value[267]. - The company is exposed to risks of employee misconduct, including non-compliance with FDA regulations, which could lead to significant penalties and reputational harm[272]. - Misconduct could result in civil, criminal, and administrative penalties, including possible exclusion from federal healthcare programs, which would adversely affect the company's operations[273]. - The company must comply with various healthcare laws, including the federal Anti-Kickback Statute and the False Claims Act, which could impact its sales and marketing activities[275]. - Non-compliance with healthcare laws may lead to penalties, reputational harm, and diminished profits, affecting future earnings and operational restructuring[274]. - The company is subject to the Foreign Corrupt Practices Act, which imposes strict accounting and compliance requirements for international operations[279]. - Data privacy and security obligations are stringent, with potential regulatory investigations and penalties for non-compliance, impacting business operations[280]. - The company faces significant fines under the California Consumer Privacy Act, which can reach up to $7,500 per intentional violation, complicating compliance efforts[282]. - The European Union's GDPR imposes fines of up to €20 million or 4% of annual global revenue for violations, increasing legal risks and compliance costs[285]. - Compliance with the Swiss Federal Act on Data Protection may lead to increased costs and risks of noncompliance penalties[286]. - The company may face significant adverse consequences if unable to lawfully transfer personal data from the EEA or UK, including increased regulatory exposure and potential fines[288]. - Compliance with data privacy and security obligations requires significant resources and may necessitate changes to information technologies and data processing practices[290]. Cybersecurity and Operational Risks - The company is subject to U.S. and foreign export controls, sanctions, and anti-corruption laws, which could impair its ability to compete in markets[294]. - Cyberattacks and malicious activities pose a threat to the confidentiality and integrity of sensitive information, with ransomware attacks becoming increasingly prevalent[298]. - The company relies on third-party service providers for critical business systems, which may expose it to cybersecurity risks and vulnerabilities[299]. - Security incidents could disrupt the company's ability to provide services and may lead to significant financial and reputational harm[302]. - The company must conduct clinical trials in compliance with Good Clinical Practices (GCP), and failure to do so could delay regulatory approvals[304]. - Regulatory authorities enforce GCP compliance through inspections, and any non-compliance could result in the need for additional clinical trials[304]. - The company may face substantial civil and criminal penalties for violations of data privacy and security laws, impacting its operations and reputation[295]. - The company’s contracts may not sufficiently limit liability related to data privacy and security obligations, and insurance coverage may be inadequate[303]. - The company relies on third-party contract research organizations (CROs) for clinical programs, which may lead to delays and impact clinical development timelines[305]. - If CROs fail to meet contractual obligations, it could result in extended or terminated clinical trials, increased costs, and delayed revenue generation[306]. - The company does not have its own manufacturing facilities and depends on third-party manufacturers, increasing the risk of insufficient product quantities or quality issues[307]. - Regulatory compliance and quality assurance are critical, as any noncompliance by third-party manufacturers could lead to significant operational disruptions[309]. - The company faces risks related to the potential noncompliance of suppliers with regulatory requirements, which could result in delays and market disruptions[310]. Intellectual Property and Market Position - The company has a license agreement with Mitsubishi Tanabe Pharma Corporation for its lead product candidate, roluperidone, which is crucial for its operations[318]. - Future milestone payments from Royalty Pharma, totaling up to $95 million, depend on the successful development and commercialization of seltorexant by Janssen Pharmaceutica NV[319]. - The company may not successfully establish new collaborations, which could adversely affect its ability to develop and commercialize future product candidates[321]. - The patent prosecution process is expensive and time-consuming, and failure to secure patents could limit the company's competitive position[322]. - The uncertainty surrounding patent rights in the biotechnology sector poses risks to the company's ability to protect its technology and products[324]. - The expiration of patents related to proprietary products may lead to increased competition and reduced ability to recover development costs, with some patents expected to expire as early as 2028[325]. - The company has in-licensed or acquired intellectual property necessary for product development, and failure to comply with obligations could result in loss of these rights[328]. - Legal proceedings to protect intellectual property may be costly and time-consuming, with the risk of competitors infringing on patents[329]. - The company may need to license additional patents from third parties, and failure to obtain these licenses could materially harm the business[330]. - Changes in patent law could diminish the value of patents, impacting the company's ability to protect its product candidates[335]. - The company faces uncertainties regarding patent protection in foreign jurisdictions, which may allow competitors to develop similar products[338]. - Compliance with procedural requirements is crucial for maintaining patent rights, as non-compliance could lead to loss of patent protection[341]. - The company may be subject to claims regarding the wrongful use of trade secrets, which could result in costly litigation and loss of valuable rights[343]. - The confidentiality of trade secrets is critical, as breaches could harm the company's competitive position[344]. Stock and Capital Structure - The market price of the company's common stock may be volatile, affecting the ability to raise capital and enter strategic partnerships[346]. - As of December 31, 2023, executive officers, directors, and holders of 5% or more of the capital stock beneficially own approximately 49.2% of the voting stock, with 19.3% held by Federated Hermes, Inc. and 18.2% held by BI[348]. - The company anticipates significant additional capital will be needed in the future to fund planned operations, including completing clinical trials for product candidates[351]. - The management is authorized to grant stock options and other equity-based awards of up to 2,078,917 shares, which may lead to additional dilution for stockholders[352]. - The company incurs significant additional legal, accounting, and compliance costs as a public company, which may divert management's time and attention[353]. - The company is classified as a "smaller reporting company," allowing it to comply with reduced reporting requirements, potentially making its securities less attractive to investors[355]. - Future sales of common stock by existing stockholders could significantly impact the market price of the company's common stock[349]. - The company may issue additional equity or debt securities in the future, which could result in further dilution for existing stockholders[351]. - The concentration of stock ownership may delay or deter a change of control and affect the market price and liquidity of the common stock[348]. - The company faces risks related to market conditions, including economic downturns and regulatory changes, which may negatively affect stock prices[347]. - The management has broad discretion over the use of proceeds from public offerings and may not apply them in ways that enhance stockholder value[350].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-36517 Minerva Neurosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 26-0784194 (State or Other Jurisdictio ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-36517 Minerva Neurosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 26-0784194 (State or Other Jurisdiction of ...

Minerva Neurosciences, Inc. (NASDAQ:NERV) Q1 2023 Earnings Conference Call May 15, 2023 8:30 AM ET Company Participants Geoff Race - President Dr. Remy Luthringer - Executive Chairman and CEO Fred Ahlholm - Senior Vice President and CFO Conference Call Participants Andrew Tsai - Jefferies Douglas Tsao - H.C. Wainwright Operator Welcome to the Minerva Neurosciences First Quarter 2023 Conference Call. At this time, all participants are in a listen-only mode. There will be a question-and-answer session followi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR For the transition period from to . (I.R.S. Employer Identification No.) Commission File No. 001-36517 Registrant's telephone number, including area code: (617) 600-7373 (Former Name, Former Address a ...

Minerva Neurosciences, Inc. (NASDAQ:NERV) Q4 2022 Earnings Conference Call March 8, 2023 8:30 AM ET Company Participants Geoff Race - President Remy Luthringer - CEO Fred Ahlholm - CFO Conference Call Participants Andrew Tsai - Jefferies Douglas Tsao - H.C. Wainwright Operator Good day, and thank you for standing by. Welcome to Minerva Neurosciences Full Year 2022 Financial Results and Business Update Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I wou ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36517 Minerva Neurosciences, Inc. (Exact name of Registrant as specified in its Charter) (State or other jurisdiction of incorporatio ...

Minerva Neurosciences, Inc. (NASDAQ:NERV) Q3 2022 Earnings Conference Call November 9, 2022 8:30 AM ET Company Participants Geoff Race - President Remy Luthringer - CEO Frederick Ahlholm - CFO Conference Call Participants Andrew Tsai - Jefferies Douglas Tsao - H.C. Wainwright Myles Minter - William Blair Operator Thank you for standing by. Welcome to the Minerva Neurosciences Third Quarter 2022 Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-36517 Minerva Neurosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 26-0784194 (State or Other Jurisdictio ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-36517 Minerva Neurosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 26-0784194 (State or Other Jurisdiction of ...